ViaCyte Announces New Board Members

SAN DIEGO, Jan. 29, 2019 -- (Healthcare Sales & Marketing Network) -- ViaCyte, Inc., a privately-held regenerative medicine company, today announced that following the recent $80 million Series D financing, the Company's Board of Directors has been restru... Regenerative Medicine, Personnel ViaCyte, islet replacement, diabetes, PEC-Direct, PEC-Encap
Source: HSMN NewsFeed - Category: Pharmaceuticals Source Type: news